Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with certain blood cancers or blood disorders, including acute myeloid leukemia, acute lymphoid leukemia (in remission), myelodysplasia (MDS), chronic lymphocytic leukemia (CLL) with little or no lymph node involvement, multiple myeloma, chronic myeloid leukemia, myelofibrosis, chronic myelomonocytic leukemia, essential thrombocytopenia, polycythemia vera, T cell leukemia, T cell lymphoma without significant lymph node disease, or other blood cancers or disorders where a stem cell transplant may offer a cure.
- People with Hodgkin or non-Hodgkin lymphoma, small lymphocytic lymphoma/CLL, aplastic anemia, or other non-cancerous blood disorders, where chemotherapy is considered more appropriate than radiation.
- People who would normally receive a more intensive (myeloablative) treatment but cannot due to prior radiation therapy or a previous intensive transplant.
- People who have a family donor who is a half-match (one haplotype mismatch), or in some cases a fully matched related donor.
- People whose heart is pumping at 50% efficiency or better, as measured by a standard heart function test.
- People whose lung function tests (diffusion capacity and breathing volume) are at least 50% of what is expected for their age and size, adjusted for blood count.
- People with liver test results within acceptable ranges (bilirubin at or below 1.8, and liver enzymes no more than 2.5 times the upper limit of normal).
- People whose kidneys are filtering at a rate of at least 60 mL per minute.
- People whose general health and ability to perform daily activities meet age-based standards — the trial site assesses this using two scoring tools (KPS and HCT-CI), with stricter requirements applying to older participants (confirm with trial site for exact thresholds by age group).
- People who are willing to use contraception if there is any possibility of becoming pregnant during the trial.
- People (or their legal guardian) who are able to give informed consent.
- People whose life expectancy is at least 6 months for reasons unrelated to their blood cancer or blood disorder.
Who may not be able to join:
- People who have another active cancer, unless it is a skin cancer that only needs local treatment.
- People who are HIV positive.
- People whose cancer has spread to the central nervous system (brain or spinal cord).
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Usama Gergis, MD, Thomas Jefferson University
Phone: 215-503-2455
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Who Experience Treatment-Related Mortality (TRM)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.